Apixaban for extended treatment of venous thromboembolism.

AMPLIFY-EXT

In patients with VTE who had completed 6 to 12 months of therapeutic anticoagulation, extended anticoagulation with apixaban at either a dose of 5 mg or a dose of 2.5 mg, as compared to placebo, reduced the risk of symptomatic recurrent VTE or death from VTE (1.7% vs. 8.8%, p < 0.001; a difference of 7.0%, 95% CI 4.9-9.1) for the 5 mg apixaban dose group and (1.7% vs. 8.8%, p < 0.001; a difference of 7.2%, 95% CI 5.0-9.3) for the 2.5 mg apixaban dose group. The rates of major bleeding for the 5 mg and 2.5 mg dose groups were 0.1% and 0.2%, respectively, vs. 0.5% for the placebo group. The corresponding rates of clinically relevant nonmajor bleeding were 4.2% and 3.0%, versus 2.3% for the placebo group.